|
The Drugs Control Officers (I) Welfare Association (DCOIWA), in coordination with the Delhi Drugs Control Administration, successfully organized a one-day national educational workshop on ‘Spurious Drugs and Investigation Skills’ at the Hotel Radisson Blu in Paschim Vihar in New Delhi recently.
Held against the backdrop of rising supply chain complexities, the seminar aimed at strengthening regulatory capacity, enhancing forensic investigation expertise, and promoting inter-agency collaboration to protect public health. The high-profile event witnessed active participation from drug control officials, regulatory experts, law enforcement authorities, and senior pharmaceutical industry representatives.
The inaugural session commenced with a welcome address by Deepak Sharma, Assistant Drugs Controller and president of the DCOIWA Delhi Chapter, who highlighted the recent enforcement achievements of the Drugs Control Department, including major raids and seizures of counterfeit medicines. Following this, G Koteshwar Rao, national president of DCOIWA, delivered the introductory address, emphasizing the growing need for coordinated, pan-India action against the menace of spurious drugs. The event was supported by key administrative guests, including Ranga Chandra Shekhar, Joint Drugs Controller (India), CDSCO, and Jayant Singh from the Narcotics Control Bureau (NCB) and NCRB, both of whom underscored the importance of central-state synergy and data integrity in monitoring pharmaceutical supply chains.
The corporate sector also marked a strong presence, with Dr. Parag Sheth, director of medical and regulatory affairs, and Lajja Saini, Head of RA at Abbott Healthcare Private Limited, being acknowledged for their valuable guidance and organizational facilitation. Senior regulatory leaders emphasized that public-private partnerships and continuous capacity-building programs are vital to fulfilling the government of India’s vision of ensuring the absolute safety, quality, and efficacy of medicines across domestic and global markets.
Technical sessions at the workshop focused heavily on modernizing prosecution and enforcement protocols. Dr Keshav Kumar, former joint director of the CBI and former Director General of Police in Gujarat, alongside Madubanti Das, delivered a comprehensive keynote on executing holistic, 360-degree investigations and securing convictions in counterfeit medicine cases. This was complemented by technical insights from Lalit Kumar Goel, former state drugs controller of Haryana, who spoke on proper storage, labelling, and packaging standards required to prevent supply chain infiltration.
The enforcement discourse was further expanded by Dr. Om Prakash Sadhwani, former Joint Commissioner and Drugs Controller, FDA Maharashtra, who trained participants on advanced investigational skills and regulatory practices under the Narcotic Drugs and Psychotropic Substances (NDPS) Act. Recognizing the high-stress environment of regulatory enforcement, the organizers also introduced a unique motivational session on stress management and balanced living, delivered by Prabhu Keshav Murari from ISKCON, which received widespread appreciation from the attending delegates.
A major highlight of the day was a hands-on technical session dedicated to the ‘Track and Trace of Spurious Drugs’, featuring a live demonstration of a Raman spectroscopy-based portable device. This session, led by Deepak Parab, CEO and managing director of Metrohm India Pvt. Ltd., along with technical experts Bhausaheb Sasawade and Sriram B, showcased how real-time, non-destructive chemical analysis can be deployed in the field by inspectors for rapid drug authentication and quality control during enforcement raids.
The workshop concluded with a formal vote of thanks by Rajeev Bhargava, Deputy Drugs Controller, Delhi DCA, who reiterated the association's commitment to holding similar educational programmes across the country to sharpen the skills of the regulatory cadre. Aligning with its core theme, ‘Together for a Safer Tomorrow’, the convention successfully served as an impactful corporate-regulatory platform for sharing actionable strategies and technological solutions to eliminate counterfeit pharmaceuticals from the healthcare ecosystem.
|